444 related articles for article (PubMed ID: 33832346)
21. TRIM25 regulates oxaliplatin resistance in colorectal cancer by promoting EZH2 stability.
Zhou S; Peng J; Xiao L; Zhou C; Fang Y; Ou Q; Qin J; Liu M; Pan Z; Hou Z
Cell Death Dis; 2021 May; 12(5):463. PubMed ID: 33966039
[TBL] [Abstract][Full Text] [Related]
22. Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer.
Zhang BY; Jones JC; Briggler AM; Hubbard JM; Kipp BR; Sargent DJ; Dixon JG; Grothey A
Clin Colorectal Cancer; 2017 Jun; 16(2):124-128. PubMed ID: 27726953
[TBL] [Abstract][Full Text] [Related]
23. A Phase I Study of Irinotecan, Capecitabine (Xeloda), and Oxaliplatin in Patients With Advanced Colorectal Cancer.
Maroun J; Marginean H; Jonker D; Cripps C; Goel R; Asmis T; Goodwin R; Chiritescu G
Clin Colorectal Cancer; 2018 Jun; 17(2):e257-e268. PubMed ID: 29330005
[TBL] [Abstract][Full Text] [Related]
24. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.
Tol J; Koopman M; Cats A; Rodenburg CJ; Creemers GJ; Schrama JG; Erdkamp FL; Vos AH; van Groeningen CJ; Sinnige HA; Richel DJ; Voest EE; Dijkstra JR; Vink-Börger ME; Antonini NF; Mol L; van Krieken JH; Dalesio O; Punt CJ
N Engl J Med; 2009 Feb; 360(6):563-72. PubMed ID: 19196673
[TBL] [Abstract][Full Text] [Related]
25. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
[TBL] [Abstract][Full Text] [Related]
26. Pretreatment serum interleukin-1β, interleukin-6, and tumor necrosis factor-α levels predict the progression of colorectal cancer.
Chang PH; Pan YP; Fan CW; Tseng WK; Huang JS; Wu TH; Chou WC; Wang CH; Yeh KY
Cancer Med; 2016 Mar; 5(3):426-33. PubMed ID: 26799163
[TBL] [Abstract][Full Text] [Related]
27. Suppression MGP inhibits tumor proliferation and reverses oxaliplatin resistance in colorectal cancer.
Huang C; Wang M; Wang J; Wu D; Gao Y; Huang K; Yao X
Biochem Pharmacol; 2021 Jul; 189():114390. PubMed ID: 33359068
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of nomograms integrating IL-37 expression, neutrophil level, and MMR status in patients with colorectal cancer.
Zhu B; Luo J; Jiang Y; Yu L; Liu M; Fu J
Cancer Med; 2018 Aug; 7(8):3682-3694. PubMed ID: 30004182
[TBL] [Abstract][Full Text] [Related]
29. Impact of the Localization of the Primary Tumor and RAS/BRAF Mutational Status on Maintenance Strategies After First-line Oxaliplatin, Fluoropyrimidine, and Bevacizumab in Metastatic Colorectal Cancer: Results From the AIO 0207 Trial.
Noepel-Duennebacke S; Arnold D; Hertel J; Tannapfel A; Hinke A; Hegewisch-Becker S; Reinacher-Schick A
Clin Colorectal Cancer; 2018 Dec; 17(4):e733-e739. PubMed ID: 30145148
[TBL] [Abstract][Full Text] [Related]
30. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
[TBL] [Abstract][Full Text] [Related]
31. Macrophages promote cell proliferation in colorectal cancer via IL-1β-mediated downregulation of miR-28-3p.
Fan HN; Liao XH; Zhang J; Zheng HM
J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1657-1668. PubMed ID: 33111515
[TBL] [Abstract][Full Text] [Related]
32. Expression of cyclooxygenase-2 parallels expression of interleukin-1beta, interleukin-6 and NF-kappaB in human colorectal cancer.
Maihöfner C; Charalambous MP; Bhambra U; Lightfoot T; Geisslinger G; Gooderham NJ;
Carcinogenesis; 2003 Apr; 24(4):665-71. PubMed ID: 12727794
[TBL] [Abstract][Full Text] [Related]
33. [Association of genetic polymorphisms in IL-6 and IL-1β gene with risk of lung cancer in female non-smokers].
Su M; Zhou B
Zhongguo Fei Ai Za Zhi; 2014 Aug; 17(8):612-7. PubMed ID: 25130968
[TBL] [Abstract][Full Text] [Related]
34. Comparison of S-1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single-center retrospective study.
Jiang Z; Sun Y; Zhang W; Cui C; Yang L; Zhou A
Asia Pac J Clin Oncol; 2020 Jun; 16(3):180-186. PubMed ID: 32077628
[TBL] [Abstract][Full Text] [Related]
35. Genetic variation in pro-inflammatory cytokines (interleukin-1beta, interleukin-1alpha and interleukin-6) associated with the aggressive forms, survival, and relapse prediction of breast carcinoma.
Snoussi K; Strosberg AD; Bouaouina N; Ben Ahmed S; Chouchane L
Eur Cytokine Netw; 2005 Dec; 16(4):253-60. PubMed ID: 16464738
[TBL] [Abstract][Full Text] [Related]
36. Bifidobacterium longum Suppresses Murine Colorectal Cancer through the Modulation of oncomiRs and Tumor Suppressor miRNAs.
Fahmy CA; Gamal-Eldeen AM; El-Hussieny EA; Raafat BM; Mehanna NS; Talaat RM; Shaaban MT
Nutr Cancer; 2019; 71(4):688-700. PubMed ID: 30862187
[TBL] [Abstract][Full Text] [Related]
37. CD16 expression on neutrophils predicts treatment efficacy of capecitabine in colorectal cancer patients.
Lu Y; Huang Y; Huang L; Xu Y; Wang Z; Li H; Zhang T; Zhong M; Gao WQ; Zhang Y
BMC Immunol; 2020 Aug; 21(1):46. PubMed ID: 32770940
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens.
Ng K; Tabernero J; Hwang J; Bajetta E; Sharma S; Del Prete SA; Arrowsmith ER; Ryan DP; Sedova M; Jin J; Malek K; Fuchs CS
Clin Cancer Res; 2013 Jul; 19(14):3987-95. PubMed ID: 23743569
[TBL] [Abstract][Full Text] [Related]
39. GALNT14 Genotype Predicts Postoperative Outcome of Stage III Colorectal Cancer With Oxaliplatin as Adjuvant Chemotherapy.
Lin WR; Chiang JM; Liang KH; Lim SN; Lai MW; Tsou YK; Hsieh TY; Hsu CK; Yeh CT
Medicine (Baltimore); 2016 Apr; 95(17):e3487. PubMed ID: 27124048
[TBL] [Abstract][Full Text] [Related]
40. ERCC1 and ERCC2 as predictive biomarkers to oxaliplatin-based chemotherapy in colorectal cancer patients from Egypt.
Kassem AB; Salem SE; Abdelrahim ME; Said AS; Salahuddin A; Hussein MM; Bahnassy AA
Exp Mol Pathol; 2017 Feb; 102(1):78-85. PubMed ID: 28088319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
